Eisai US - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeEisai US
Eisai US logo

Eisai US

0 followers

4523

Performance

About Eisai US

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., dedicated to human health care (hhc) by prioritizing the needs of patients and their families. Based in New Jersey, Eisai focuses on developing innovative therapies primarily in the fields of oncology and neurology, particularly addressing dementia-related and neurodegenerative diseases. The company integrates discovery, development, and marketing efforts across various locations, including Massachusetts and Pennsylvania for research and Maryland and North Carolina for global demand chain operations.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Tatsuyuki Yasuno

Chairman & Chief Executive Officer, President, Americas Region

Lynn D. Kramer, M.D., FAAN

Chief Clinical Officer, Deep Human Biology Learning (DHBL)

Katsuya Haruna

Senior Group Officer & Executive Vice President, US Business Operations

Key Facts

HQ Location

Nutley, United States

Founded

1995

Employees

1K-5K

Status

Public

Website

https://eisai.com